Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,longTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,GBT,363195000.0,62266800,50857000,,-74930000,,-74930000,58966000,38459000,-71364000,-71364000,,-3689000,,,,0,39043000,110407000,584000,-3566000,,-74930000,-74930000,1424411000.0,286703000.0,363195000.0,7010000.0,649898000.0,62000.0,-1061399000.0,822000.0,121000.0,3631000.0,445310000.0,58967000.0,121000.0,88135000.0,558132000.0,36736000.0,18265000.0,149052000.0,42267000.0,10376000.0,,,29134000.0,-8544000.0,28004000.0,1780000.0,-15749000.0,3703000.0,-49472000.0,-1897000.0,-79256000.0,1404000.0,-1569000.0,-765000.0,-26000.0,20897000.0,-1130000.0,,499165000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,29.85,1630526403,1.1599998,28.83,29.88,28.6,848444,0,"Global Blood Therapeutics, Inc.",POST,us_market,-3.852595,1630531885,28.7,-1.1499996,4.04322,28.6 - 29.88,28.69,28.7,30.0,10,14,finmb_208736100,NasdaqGS,"Global Blood Therapeutics, Inc.",USD,1297292,1112000,4.370001,0.1715071,25.48 - 64.489,-34.639,-0.53713036,25.48,64.489,1620244800,1635937140,1636372800,0.008199985,37.53993,-7.689928,-0.20484664,-10.153061,-4.046,-2.94,-4.51,-6.618625,5.835,29.607222,0.24277878,1858664064,5.115681,15,America/New_York,EDT,-14400000,False,False,1.08,,,64.49,25.48,29.61,37.54,1.3M,1.11M,62.27M,,52.45M,2.42%,112.54%,11.5M,13.54,18.92%,18.47%,11.6M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-167.73%,-162.76%,-21.75%,-56.26%,148.73M,2.41,176.50%,121.82M,-236.48M,-249.46M,-4.05,,482.05M,7.74,231.95M,63.86,9.47,5.84,-212.5M,-130.56M,Value,94080,Healthcare,389,10,2,"Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.",South San Francisco,650 741 7700,CA,8,1609372800,1622505600,9,United States,http://www.gbt.com,86400,10,181 Oyster Point Boulevard,Biotechnology
t-1,GBT,416157000.0,62266800,41068000,,-61806000,,-61806000,59624000,40334000,-60358000,-60358000,,-2922000,,,,0,41295000,101653000,961000,-1448000,,-61806000,-61806000,1402262000.0,307845000.0,416157000.0,6405000.0,724002000.0,62000.0,-986469000.0,822000.0,302000.0,3235000.0,494766000.0,79032000.0,302000.0,88604000.0,632163000.0,66126000.0,17500000.0,148815000.0,40223000.0,19078000.0,949000.0,,50174000.0,11195000.0,45610000.0,75839000.0,-6911000.0,1034000.0,76383000.0,-124000.0,-45066000.0,3898000.0,-5926000.0,-3370000.0,130000.0,17854000.0,-4564000.0,74799000.0,553131000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,29.85,1630526403,1.1599998,28.83,29.88,28.6,848444,0,"Global Blood Therapeutics, Inc.",POST,us_market,-3.852595,1630531885,28.7,-1.1499996,4.04322,28.6 - 29.88,28.69,28.7,30.0,10,14,finmb_208736100,NasdaqGS,"Global Blood Therapeutics, Inc.",USD,1297292,1112000,4.370001,0.1715071,25.48 - 64.489,-34.639,-0.53713036,25.48,64.489,1620244800,1635937140,1636372800,0.008199985,37.53993,-7.689928,-0.20484664,-10.153061,-4.046,-2.94,-4.51,-6.618625,5.835,29.607222,0.24277878,1858664064,5.115681,15,America/New_York,EDT,-14400000,False,False,1.08,,,64.49,25.48,29.61,37.54,1.3M,1.11M,62.27M,,52.45M,2.42%,112.54%,11.5M,13.54,18.92%,18.47%,11.6M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-167.73%,-162.76%,-21.75%,-56.26%,148.73M,2.41,176.50%,121.82M,-236.48M,-249.46M,-4.05,,482.05M,7.74,231.95M,63.86,9.47,5.84,-212.5M,-130.56M,Value,94080,Healthcare,389,10,2,"Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.",South San Francisco,650 741 7700,CA,8,1609372800,1622505600,9,United States,http://www.gbt.com,86400,10,181 Oyster Point Boulevard,Biotechnology
t-2,GBT,457655000.0,62266800,40196000,,-59881000,,-59881000,54491000,36376000,-58311000,-58311000,,-2291000,,,,0,36889000,95200000,513000,-1570000,,-59881000,-59881000,1381537000.0,233609000.0,457655000.0,,691264000.0,61000.0,-924663000.0,1344000.0,720000.0,3291000.0,418402000.0,77946000.0,720000.0,90034000.0,594664000.0,113523000.0,14130000.0,73880000.0,33808000.0,7882000.0,,3275000.0,72090000.0,2097000.0,71818000.0,2583000.0,3329000.0,5574000.0,33708000.0,-2991000.0,-40693000.0,1348000.0,-5927000.0,-1659000.0,130000.0,20000000.0,-272000.0,74799000.0,516718000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,29.85,1630526403,1.1599998,28.83,29.88,28.6,848444,0,"Global Blood Therapeutics, Inc.",POST,us_market,-3.852595,1630531885,28.7,-1.1499996,4.04322,28.6 - 29.88,28.69,28.7,30.0,10,14,finmb_208736100,NasdaqGS,"Global Blood Therapeutics, Inc.",USD,1297292,1112000,4.370001,0.1715071,25.48 - 64.489,-34.639,-0.53713036,25.48,64.489,1620244800,1635937140,1636372800,0.008199985,37.53993,-7.689928,-0.20484664,-10.153061,-4.046,-2.94,-4.51,-6.618625,5.835,29.607222,0.24277878,1858664064,5.115681,15,America/New_York,EDT,-14400000,False,False,1.08,,,64.49,25.48,29.61,37.54,1.3M,1.11M,62.27M,,52.45M,2.42%,112.54%,11.5M,13.54,18.92%,18.47%,11.6M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-167.73%,-162.76%,-21.75%,-56.26%,148.73M,2.41,176.50%,121.82M,-236.48M,-249.46M,-4.05,,482.05M,7.74,231.95M,63.86,9.47,5.84,-212.5M,-130.56M,Value,94080,Healthcare,389,10,2,"Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.",South San Francisco,650 741 7700,CA,8,1609372800,1622505600,9,United States,http://www.gbt.com,86400,10,181 Oyster Point Boulevard,Biotechnology
t-3,GBT,495816000.0,62266800,34085000,,-52840000,,-52840000,49075000,31124000,-52036000,-52036000,,-2282000,,,,0,31501000,83537000,377000,-804000,,-52840000,-52840000,1359310000.0,225851000.0,495816000.0,30000.0,721667000.0,61000.0,-864782000.0,771000.0,1227000.0,2907000.0,384716000.0,69402000.0,1227000.0,91248000.0,594033000.0,156014000.0,12471000.0,73775000.0,27334000.0,5690000.0,,33479000.0,110152000.0,-7485000.0,108758000.0,7914000.0,12196000.0,8032000.0,69191000.0,-73000.0,-47481000.0,1439000.0,-11708000.0,-7893000.0,-45000.0,18810000.0,-1394000.0,74799000.0,524631000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,29.85,1630526403,1.1599998,28.83,29.88,28.6,848444,0,"Global Blood Therapeutics, Inc.",POST,us_market,-3.852595,1630531885,28.7,-1.1499996,4.04322,28.6 - 29.88,28.69,28.7,30.0,10,14,finmb_208736100,NasdaqGS,"Global Blood Therapeutics, Inc.",USD,1297292,1112000,4.370001,0.1715071,25.48 - 64.489,-34.639,-0.53713036,25.48,64.489,1620244800,1635937140,1636372800,0.008199985,37.53993,-7.689928,-0.20484664,-10.153061,-4.046,-2.94,-4.51,-6.618625,5.835,29.607222,0.24277878,1858664064,5.115681,15,America/New_York,EDT,-14400000,False,False,1.08,,,64.49,25.48,29.61,37.54,1.3M,1.11M,62.27M,,52.45M,2.42%,112.54%,11.5M,13.54,18.92%,18.47%,11.6M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-167.73%,-162.76%,-21.75%,-56.26%,148.73M,2.41,176.50%,121.82M,-236.48M,-249.46M,-4.05,,482.05M,7.74,231.95M,63.86,9.47,5.84,-212.5M,-130.56M,Value,94080,Healthcare,389,10,2,"Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.",South San Francisco,650 741 7700,CA,8,1609372800,1622505600,9,United States,http://www.gbt.com,86400,10,181 Oyster Point Boulevard,Biotechnology
